RAPGEF3 and prostate cancer: Our previous studies of Epac-mediated events in prostate cancer were in response to the observation that ligation of the α2-macroglobulin-proteinase (α2M*) cell surface signaling receptor, GRP78, results in activation of Gs-mediated cAMP production [56].